

CAMZYOS® REMS Drug Interaction and Counseling Checklist for Pharmacies

Instructions:

Complete this form prior to each dispense of CAMZYOS. Complete online at **CAMZYOSREMS.com** or fax the completed form to the CAMZYOS REMS at 833-299-9539. Do not dispense CAMZYOS until the authorization to dispense is received.

Step 1:

Patient Information (Fields marked * are REQUIRED)		
*First Name:	Middle Initial:	*Last Name:
*Date of Birth:		
Month/Day/Year		

Healthcare Provider Information (Fields marked * are REQUIRED)		
*First Name:	*Last Name:	
NPI #:	Phone:	
	Area Code/Telephone Number	

Pharmacy Information (Fields marked * are REQUIRED)				
*Pharmacy Name:	*Pharmacy NPI #:			
*Pharmacy Address:	*City:	*State:	*ZIP Code:	
Phone:				
Area Code/Telephone Number				

This is a:	□ New prescription	\Box Refill at the same	dose 🗌 Restart	after temporary interruption	Dose increase
	🗌 Dose decrease (r	ationale):			
	□ LVEF <50%	VLVOT <20 mmHg 🗌 Drug interaction 🗌 Other not listed on Patient Status Form		Status Form	



For internal use only



© 2025 MyoKardia, Inc., a Bristol Myers Squibb company. CAMZYOS® and the CAMZYOS Logo are trademarks of MyoKardia, Inc. All other trademarks are the property of their respective owners. 3500-US-2500195 04/25

CAMZYOS® REMS

Drug Interaction and Counseling Checklist for Pharmacies

Step 2: Drug Interaction Screening	
I have reviewed the patient's current medical conditions for which they are under a healthcare provider's care List current medical conditions for which they are under a healthcare provider's care.	•
 I have reviewed with the patient their current prescription and nonprescription medications and supplements. List the current prescription and nonprescription medications and supplements that the patient is currently taking 	
List any new prescription or nonprescription medications or supplements since the last fill of CAMZYOS. (If this is the first prescription, move to Question 1.)	_
 Check ALL current medications and supplements for contraindications (strong CYP2C19 inhibitors, moderate to strong CYP2C19 inducers, or moderate to strong CYP3A4 inducers). If contraindicated medication(s) are found, do not fill CAMZYOS and contact the healthcare provider. 	_
a. Is the patient taking a contraindicated medication? \square Yes \square No	
If yes, please provide the contraindicated medication(s):	
 Check for drug interactions that require dose adjustment (moderate to strong CYP3A4 inhibitors or weak to moderate CYP2C19 inhibitors). If found, do not fill CAMZYOS, and contact the healthcare provider for dos adjustment. If the CAMZYOS dose is already adjusted, contacting the healthcare provider is not necessary. Note: 	se
 Patients who are on stable therapy with a moderate CYP3A4 inhibitor or a weak CYP2C19 inhibitor prior to initiating CAMZYOS should initiate CAMZYOS at the recommended 5-mg starting dose 	
 Patients who are on stable therapy with a strong CYP3A4 inhibitor or a moderate CYP2C19 inhibitor prior to initiating CAMZYOS should initiate CAMZYOS at a 2.5-mg starting dose 	
a. Is the patient taking a medication that requires a CAMZYOS dosage adjustment? \Box Yes \Box No	
If yes, please provide the medication(s) that require(s) a CAMZYOS dosage adjustment:	
3. The interacting medication/supplement was prescribed/recommended by:	_
A CAMZYOS-certified healthcare provider/designee Month/Day/Year	
□ Other healthcare provider/designee	
Purchased over the counter by patient	
Contacted healthcare provider via on	-
Action taken for contraindicated medication(s):	
CAMZYOS discontinued Other medication(s) discontinued	
 Action taken for medication(s) requiring dosage adjustment: CAMZYOS discontinued CAMZYOS dose decreased Other medication(s) discontinued 	

For internal use only

(^{III}) Bristol Myers Squibb[°]

Phone: 833-628-7367 Fax: 833-299-9539 CAMZYOSREMS.com

CAMZYOS® REMS


Drug Interaction and Counseling Checklist for Pharmacies

Step 3: Counseling			
failure such as shortness of □ I have instructed the patien	breath, chest pain, fatigue, palpitatio	of new or worsening symptoms of heart ons, leg swelling, and rapid weight gain. nd pharmacy prior to the use of any new rior to stopping any medication.	
Pharmacist Name:		Date: Month/Day/Year	
	aindicated With CAMZYOS—DC	NOT DISPENSE CAMZYOS*	
Strong CYP2C19 InhibitorsDiflucan (fluconazole)Prozac (fluoxetine)Luvox (fluvoxamine)60 mg once daily		Ticlid (ticlopidine) Vfend (voriconazole)	
Moderate to Strong CYP	2C19 Inducers or Moderate to	Strong CYP3A4 Inducers	
Cerebyx (fosphenytoin)	Mysoline (primidone)	Sustiva (efavirenz)	
Dilantin (phenytoin)	Nafcillin	Tracleer (bosentan)	
Erleada (apalutamide)	Phenobarbital	Tegretol (carbamazepine)	
Intelence (etravirine)	Rifadin (rifampin)	Xtandi (enzalutamide)	
Lysodren (mitotane)	St. John's wort		

*This table contains select examples and is not comprehensive.



For internal use only



© 2025 MyoKardia, Inc., a Bristol Myers Squibb company. CAMZYOS® and the CAMZYOS Logo are trademarks of MyoKardia, Inc. All other trademarks are the property of their respective owners. 3500-US-2500195 04/25 Phone: 833-628-7367 Fax: 833-299-9539 CAMZYOSREMS.com

CAMZYOS® REMS Drug Interaction and Counseling Checklist for Pharmacies

Examples of Drugs That Interact With CAMZYOS—Dose of CAMZYOS Must Be Adjusted*

Please see CAMZYOS Prescribing Information.

Note: patients who are on stable therapy with a weak CYP2C19 inhibitor or a moderate CYP3A4 inhibitor prior to initiating CAMZYOS should initiate CAMZYOS at the recommended 5-mg starting dose. Patients who are on stable therapy with a strong CYP3A4 inhibitor or a moderate CYP2C19 inhibitor prior to initiating CAMZYOS should initiate CAMZYOS at 2.5-mg starting dose.

Weak CYP2C19 Inhibitors or Moderate CYP3A4 Inhibitors

Calan (verapamil) Cardizem (diltiazem) Cipro (ciprofloxacin)	Erythromycin Multaq (dronedarone) Nydrazid (isoniazid)	Prilosec (omeprazole) 20 mg once daily Tagamet (cimetidine)
Strong CYP3A4 Inhibitors Biaxin (clarithromycin) Grapefruit juice Nizoral (ketoconazole) Noxafil (posaconazole)	Ritonavir-containing products (eg, Norvir, Paxlovid, Kaletra) Serzone (nefazodone) Sporanox (itraconazole)	Tybost (cobicistat) Viracept (nelfinavir) Zydelig (idelalisib)
Moderate CYP2C19 Inhibitors Felbatol (felbamate) Nexium (esomeprazole)	5 Prilosec (omeprazole) 40 mg once daily	Prozac (fluoxetine) 20 mg once daily or less

*This table contains select examples and is not comprehensive.



For internal use only

(^{III}) Bristol Myers Squibb[°]

 $^{\odot}$ 2025 MyoKardia, Inc., a Bristol Myers Squibb company. CAMZYOS® and the CAMZYOS Logo are trademarks of MyoKardia, Inc. All other trademarks are the property of their respective owners. 3500-US-2500195 04/25 Phone: 833-628-7367 Fax: 833-299-9539 CAMZYOSREMS.com